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RAPID COMMUNICATION

Hematopoietic Defects in Mice Lacking the Sialomucin CD34
By J. Cheng, S. Baumhueter Although the pluripotent hematopoietic stem cell can only be definitively identified by its ability to reconstitute the various mature blood lineages, a diversity of cell surface antigens have also been specifically recognized on this subset of hematopoietic progenitors. One such stem cell-associated antigen is the sialomucin CD34, a highly 0-glycosylated cell surface glycoprotein that has also been shown to be expressed on all vascular endothelial cells throughout murine embryogenesis as well as in the adult. The functional significance of CD34 expression on hematopoietic progenitor cells and developing blood vessels is unknown. To analyze the involvement of CD34 in hematopoiesis, we have produced both embryonic stem (ES) cells and mice that are null for the expression of this mucin. Analysis of yolk saclike hematopoietic development in embryoid bodies derived from CD34-null ES cells showed a significant delay in both erythroid and myeloid differentiation that could be reversed by transfection of the mutant ES cells with CD34 constructs expressing either a complete or truncated cytoplasmic domain. Measurements of colony-forming activity of hematopoietic progenitor cells derived from yolk sacs or fetal livers F THE DIVERSITY OF antigens expressed by the pluripotential stem cell fraction of the hematopoietic compartment, the sialomucin CD34 is one of the most commonly used for stem cell purification.I4 This glycoprotein consists of a large extracellular domain containing an extensively 0-glycosylated mucin-like region as well as a cysteine-rich Early studies in humans as well as lower primates showed that the CD34+ fraction of bone marrow (BM) and peripherally mobilized progenitor cells contained stem cells that were able to reconsitute all of the blood lineages after transplantation. '32 More recently, data in the murine system have shown that mouse BM and fetal liver also contain a CD34+ subset that is able to reconstitute the hematopoietic potential of lethally irradiated Interestingly, it has been recognized for some time that the expression of CD34 diminishes as hematopoietic cells mature, and completely differentiated blood cells do not express the antigen at all, a result that is consistent with a potential role for this mucin in early hematopoietic de~elopment.'.'~ In addition, we and others have recently shown that this antigen is expressed on hematopoietic progenitor cells throughout murine embryogenesis at a diversity of hematopoietic sites, including the yolk sac blood islands, the aortic-gonadal-mesonephros (AGM) region, the fetal liver, and the fetal BM.".'2 We have also found that the CD34+ fractions derived from the murine yolk sac and embryo at days 9 to 11 contain the majority of myeloid and erythroid colony-forming unit activity as well as progenitor cells capable of expansion on yolk sac endothelial cell lines (see below; Fennie et a l l 3 and C. Fennie and L. Lasky, unpublished observations). Thus, in support of its potential importance to hematopoietic cell function, these data together show that the CD34 mucin is expressed on hematopoietic stem and progenitor cells from the very onset of embryonic hematopoiesis as well as throughout later embryonic and adult hematopoietic development. isolated from CD34-null embryos also showed a decreased number of these precursor cells. In spite of these diminished embryonic hematopoietic progenitor numbers, the CD34-null mice developed normally, and the hematopoietic profile of adult blood appeared typical. However, the colony-forming activity of hematopoietic progenitors derived from both bone marrow and spleen is significantly reduced in adult CD34-deficient animals, and these CD34-deficient progenitors also appear to be unable to expand in liquid cultures in response to hematopoietic growth factors. Even with these apparent progenitor cell deficiencies, CD34-null animals showed kinetics of erythroid, myeloid, and platelet recovery after sublethal irradiation that are indistinguishable from wild-type mice. These data strongly suggest that CD34 plays an important role in the formation of progenitor cells during both embryonic and adult hematopoiesis. However, the hematopoietic sites of adult CD34-deficient mice may still have a significant reservoir of progenitor cells that allows for normal recovery after nonmyeloablative peripheral cell depletion.
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In addition to its expression on hematopoietic progenitor cells, CD34 is also expressed on all vascular endothelial cells of both embryos and adults, a finding that suggests a potentially important role for this sialomucin in blood vessel foma~on.lL, 12, [14] [15] [16] Perhaps, most interesting with respect to hematopoiesis is the finding that this mucin is found on the endothelial cells lining the yolk sac blood islands. Because blood island hematopoietic progenitor cells are in contact with these CD34+ endothelial cells, it is likely that the growth and differentiation of these hematopoietic cells is at least in part controlled by factors produced by these endothelial cells. In support of this supposition, isolation of the CD34+ endothelium from the blood islands of day 10 to 11 yolk sacs and transformation with the polyoma middle Tantigen oncogene has led to the isolation of a number of CD34' endothelial cell lines that are able to induce the expansion of isolated CD34' yolk sac cells up to 60-fold along the myeloid pathway.I3 In addition, the supplementation of exogenous erythropoietin (EPO) in these cocultures induced the differentiation of mature hemoglobin-positive erythroid cells from undifferentiated CD34+ yolk sac progenitors. These yolk sac lines were also able to expand myeloid and erythroid progenitors in addition to an even earlier, less differentiated progenitor cell type, the lin'"CD34h'scah' population, a subset of hematopoietic cells that likely contains the pluripotent stem cell (C. Fennie and L. Lasky, unpublished data). These results suggested that the CD34+ endothelium lining the yolk sac blood islands interacts with the CD34' hematopoietic progenitor cells of the yolk sac to induce growth, differentiation and, possibly, self-renewal of the pluripotent stem cell population. It is also possible that similar hematopoietic progenitor-endothelial cell interactions occur in the AGM region of the embryo as and we have recently found that intraembryonic hematopoietic progenitor cells associated with the AGM region, as well as other hematopoietic sites, in mice are clearly positive for CD34 (F. Dieterlein-Lievre, I. Godin, and L. Lasky, unpublished data).
Although the above data suggested a potentially interesting association of CD34 with both hematopoietic progenitor cells as well as endothelial cells, the function of this mucin has been difficult to delineate. Perhaps the clearest functional data have been derived from studies showing that the 0-linked, specially modified polylactosamine carbohydrates found on CD34 expressed by the high endothelial venules of peripheral lymph nodes interact with the lectin domain of the lymphocyte adhesion molecule, L-selectin." It is likely that this binding event mediates, at least in part, the adhesive interactions between lymphocytes and the endothelium that direct the migration of these cells to these lymphoid tissues. In support of this hypothesis, recent work has shown that appropriately 0-glycosylated CD34 isolated from human tonsils can mediate the L-selectin-dependent rolling adhesion of lymphocytes in parallel-plate laminar-flow systems.'" However, although these results are consistent with potential adhesive functions for peripheral lymph node vascular CD34, the function of CD34 on hematopoietic progenitors and on the vascular endothelium of the embryo is not understood. With respect to hematopoiesis, other data have suggested that two serines in the cytoplasmic domain of CD34 are phosphorylated in response to protein kinase C activation of hematopoietic cell lines, consistent with a potential function for this mucin in cell activation." Along these lines, protein kinase C treatment of hematopoietic cell lines also upregulates the surface expression of CD34. Other work has shown that antibodies directed against CD34 can trigger homotypic adhesion between hematopoietic progenitor cells that is mediated by a p1 integ~in.*~.'~ Together, these in vitro data are consistent with a potential role for the CD34 mucin in the regulation of hematopoiesis, perhaps via unspecified cell signaling or adhesion pathways.
To begin to analyze the potential functional significance of CD34 to the hematopoietic system in a more physiological context, we have produced both embryonic stem (ES) cells and mice that are null for the expression of this mucin. We show here that the loss of this glycoprotein results in clear effects on hematopoietic development in embryoid bodies in vitro as well as significant deficiencies in the levels of progenitor cells in both embryonic and adult hematopoietic systems. In addition, we also show that the lack of this mucin results in major deficiencies in the in vitro expansion of adult hematopoietic progenitor cells in response to various growth factors. Interestingly, these progenitor cell defects are not mirrored as deficiencies in the steady-state levels of mature blood cells nor in the ability of the hematopoietic system to replenish peripheral blood cells ablated by sublethal radiation. Together, these argue for an important physiological role for CD34 in embryonic and adult hematopoiesis.
MATERIALS AND METHODS
Derivation of ES cells and mice mutated at the CD34 locus. The 129/Sv-derived ES cell line D3 was adapted to grow in the presence of leukemia inhibitory factor (LIF), which replaced the feeder cells in maintaining the totipotency of ES cells. Cells are routinely passed in Dulbecco's modified Eagle's medium (DMEM) supplement with 1.000 U/mL LIF, 0.144 mmoUL monothioglycerol (MTG), 2 mmol/ L L-glutamine, and 15% fetal bovine serum (FBS; ES growth medium) on gelatin-treated tissue-culture plates. A 6.2-kb BamHI fragment was subcloned from a genomic h clone encoding the CD34 gene.5 The fragment was digested with BssHI, and the resultant fragment was ligated to neomycin gene cassette. The resultant fragment was transfected into the D3 ES cell line, and neomycin-resistant clones were selected. Several hundred clones were analyzed by Nde I digest using an -500-bp EcoRI-BamHI fragment derived from a region S' to the targetting fragment. ES clones containing a homologous recombinant were either injected into mouse blastocysts or were selected for a mutation in the second CD34 allele by isolating clones resistant to gradually increasing levels of neomycin. Germ line transmission of the mutant CD34 allele was established by coat color, and homozygous animals were bred.
Production of ES cells transfected with CD34 constructs. Doubly mutated ES cells that were null for the expression of CD34 (see above) were cotransfected by electroporation (ElectroCell Manipulator 600; Baxter Inc, Hayward, CA) with plasmids expressing either the full-length (CD34-FL) or truncated (CD34-SDP) forms of the murine CD34 cDNA under the control of the cytomegalovirus (CMV) early promoter together with a plasmid encoding the hygromycin-resistance gene under the control of the same promoter at a 1O:l molar ratio. The CD34-SDP construct was deleted of all but the 6 C-terminal amino acids of the CD34 cytoplasmic domain. In addition, the construct inserted the sequence ELEP (glutamate, leucine, glutamate, proline) before the engineered stop codon. Two days after electroporation, the growth medium was replaced with medium containing 300 mg/mL hygromycin. After 10 to 12 days, hygromycin-resistant ES cells were first incubated with affinity-purilied anti-CD34 antibody (rabbit IgG; 2 mg/mL), washed to remove the unbound antibody, and then passed through columns packed with magnetic beads that had been coated with antirabbit IgG antibody (Mini Mac; Miltenyi Biotec, Inc, Auburn, CA). CD34-expressing ES cells were collected from the column after removal from the magnetic field and put into growth medium containing hygromycin. After 7 days, the cells were analyzed by fluorescence-activated cell sorting (FACS) scan to confirm the expression of CD34.
Analysis of embryoid body hematopoietic development. Embryoid bodies were induced to form hematopoietic structures as described previously." ES cell cultures were dissociated into single cells by trypsinization. Dispersed ES cells were seeded into semisolid differentiation medium composed of Iscove's modified Dulbecco's medium (IMDM), 300 mg/mL of iron-saturated transferrin, 0.45 mmol/L MTG, 0.1 mmoW P-mercaptoethanol, IO mg/mL bovine insulin, 2 mmoVL L-glutamine, 1% methylcellulose, and 15% FBS (ES-qualified FBS GIBCO-BRL, Gaithersburg, MD). A specific lot of FBS that had been tested to provide the most efficient embryoid use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From body formation was used. A total of 800 ES cells were plated in a final volume of 1.5 mL medium in 35-mm diameter bacterial-grade dishes. To assess the capacity of hematopoietic development for different ES cell lines, 50 U/mL interleukin-3 (IL-3), 1,000 U/mL IL-1, and either 50 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) or 5 U/mL EPO were supplemented into the medium. The embryoid bodies that developed hematopoietic cells of the monocyte/macrophage lineage were evident by the large halo of macrophages surrounding the embryoid body (as confirmed by Wright-Giemsa staining of dissociated embryoid bodies). The development of erythroid cells was assessed by benzidine staining of the embryoid body (as confirmed by Wright-Giemsa and benzidine staining of dissociated embryoid bodies).
Analysis of colonylforming unitsfrom embryos and adults. Total nucleated cell populations were isolated from either fetal (yolk sac or liver) or adult (spleen or BM) hematopoietic organs. For fetal tissues, individual yolk sacs from 10.5-day embryos or livers from 14.5-day embryos were dissected and rinsed 3 times in IMDM with 15% FBS. To prepare single-cell suspension, each of the fetal yolk sacs was treated with 2 mg/mL collagenase/dispase in IMDM at 37°C with shaking for 1 hour. Each of the fetal livers was passed 5 times through a 22-gauge syringe. Cell suspensions were placed on ice and washed twice in IMDM with 15% FBS. The number of cells in each sample was determined, and cell samples were seeded at 1 6 (fetal liver) or lo6 (yolk sac) cells per culture in methylcellulose medium supplemented with various hematopoietic growth factors. For the colony-formation of the myeloid progenitor cells (CFU-GM), 500 U/mL IL-1, 25 U/mL IL-3, and 25 U/mL GM-CSF were supplemented in the semisolid differentiation medium. For the colony formation of the erythroid progenitor cells (BFU-E), IL-l, IL-3, and 5 U/mL EPO were supplemented. For total colony-forming activity (CFU-C), both EPO and GM-CSF were included. The genotypes of the individual embryos from which the yolk sacs or fetal livers were obtained was determined by the polymerase chain reaction (PCR). For the analysis of adult progenitors, colony-forming activity was determined by plating unseparated BM or spleen cells, respectively, at 50,000 and 500,000 cells/mL in 1% methylcellulose culture medium containing 30% FBS, 1 U/mL EPO, 100 U/mL GM-CSF, 50 ng/mL Steel factor, and 0.1 mmol/L hemin for 7 days. To analyze the ability of progenitor cells to expand in vitro, unseparated BM cells were plated in suspension culture for 7 days with 10% FBS, 1 U/mL EPO, 100 U/mL GM-CSF, 50 ng/mL Steel factor and 100 ng/mL FLT3-ligand. Colony-forming activity of these cells was examined in methylcellulose cultures before and after this in vitro expansion period, as was the total number of nucleated cells.
Analysis of blood reconstitution in sublethally irradiated mice. All animal studies were approved by the Institutional Care and Use Committee of Genentech Inc. Before the start of the experiment, all animals were ear-tagged for identification, and a base-line complete blood count (CBC) was obtained. Groups of 10 mice were irradiated with 7.5 Cy of y-irradiation from a I3'Cs source. Before the experiment and at 3-to 4-day intervals throughout the study, 40 pL of blood was obtained from the orbital sinus and immediately diluted into 10 mL of diluent to prevent clotting. The CBC from each blood sample was measured on a Serrono Baker system 9018 blood analyzer within 60 minutes of collection. Only half of the animals in each dose group were bled on a given day; thus, each animal was bled on alternate time points.
RESULTS
Mutation of the CD34 locus. To produce a null mutation at the CD34 locus, the murine CD34 gene was isolated (Fig  l) .5,25 A 6.2-kb BamHI genomic DNA fragment containing the amino terminal coding region of this mucin was subcloned, and a neomycin-resistance gene was inserted into a BssH2 site within the coding region of the signal sequence exon. This insertion disrupts the reading frame of the signal sequence and should result in a protein that could not be transported through the cell's secretion pathway to the cell surface. The construct was transfected into ES cells, and the neomycin-resistant colonies were screened using an EcoW BamHI probe derived from a 5' region outside of the gene targeting construct. Analysis of DNA from several clones using NdeI restriction digestion, which releases an approximately 6.2-kb wild-type and an approximately 8.2-kb homologously disrupted CD34 gene, showed three neomycin-resistant clones with mutations of the CD34 locus (data not shown).
To analyze the role of CD34 in hematopoiesis during embryoid body formation in cell culture, the second CD34 locus was disrupted by gene conversion. Neomycin levels were gradually increased, and surviving ES colonies that were initially heterozygous for the CD34 disruption were analyzed at each concentration for conversion of the remaining wild-type CD34 locus to the mutant, neomycincontaining locus. As can be seen from Fig 2, ES cells constituitively express CD34; therefore, the clones containing two mutant copies of the CD34 gene, as determined by the PCR and Southern blot analysis, could be analyzed by FACS scanning using the antimurine CD34 polyclonal antibody.16 Figure 2 shows that a doubly mutated clone detected by Southern blot and PCR analyses, termed 1-8D, showed a complete loss of surface expression of CD34, which is consistent with a null mutation at both alleles. Finally, analysis of CD34 expression on blood vessels16 of adult animals bred to be homozygous for mutation at the CD34 locus also showed that the insertion of the neomycin-resistance gene in the signal sequence exon resulted in a null mutation (Fig  3) .
Analysis of hematopoiesis in CD34-null embryoid bodies. Previous data have shown that ES cells can differentiate in cell culture into embryoid bodies containing yolk sac-like structures.24 These yolk sac-like structures can be induced to form both the erythroid and myeloid lineages of differentiated hematopoietic cells when cultured in the presence of various growth factor combinations. Indeed, analysis of embryoid bodies with antibodies directed against CD34 showed primitive vascular structures reminiscent of those observed in the yolk sac as well as occasional CD34-positive hematopoietic progenitor cells (Young et all' and S. Baumhueter and L. Lasky, unpublished observations). This model system provided an opportunity to analyze the role of CD34 in the production of these differentiated ES-derived blood cells. As can be seen from Fig 4, staining of day-l0 embryoid bodies grown in the presence of EPO, IL-1, and IL-3 with benzidine showed that many hemoglobinized erythroid cells could be detected (Fig 4) . However, analysis of day-l2 embryoid body formation using the 1-8D clone deficient in CD34 production showed a clear reduction of erythroid development in the presence of EPO at this time (Fig 4) . However, whereas there was a clear reduction of erythroid development at day 12, significant, although decreased, erythroid development was observed at later time points. In agreement use only. with this observation, the induction of monocyte/macrophage development in the presence of GM-CSF was clearly retarded in the 1-8D clone (CD34"-) as compared with that in the wild-type ES line. Investigation of a time course of monocyte/macrophage development in this system shown that this defect was not absolute, but was temporal (Fig 5) . Thus, the CD34-deficient clone showed significant monocyte/macrophage development, although with a lag time of several days as compared with that of the wild-type ES cells (Fig 5) . In addition, whereas myeloid development clearly occurred, it was not as complete as that in the wild-type cells, with only approximately 25% of mutant embryoid bodies positive for macrophages as compared with the approximately 35% of the wild-type embryoid bodies positive for macrophage development at 25 days of culture (Fig 5) . Thus, these data suggested that the loss of CD34 resulted in defects in the differentiation of both erythroid and myeloid cells from embryoid body progenitor cells, although the defects were not absolute.
To determine if the blood cell defects found in mutant embryoid bodies could be rescued by overexpression of CD34, and to determine the potential functional importance of the cytoplasmic domain of CD34, the 1-8D double-mutant ES cells were transfected with two different CD34 constructs. One construct contained the entire cytoplasmic domain (FL), including the known protein kinase C-dependent phosphorylation sites, whereas the other construct was essentially deleted for the majority of the cytoplasmic domain (SDP; see Materials and Methods). Hygromycin-resistant ES clones were isolated and analyzed for CD34 expression by FACS analysis using the antimurine CD34 polyclonal antibody. As can be seen from Fig 2, both forms of CD34 were expressed on the surface of the transfected ES cells originally derived from the CD34-null 1-8D cell line, although this expression occurred at higher levels than that in the wildtype clone C-12. This higher level of expression was likely because of the strong CMV promoter that was used for the transcription of these transfected constructs. In addition, the use of the CMV promoter would be likely to induce the expression of CD34 in a number of embryoid body cells, as opposed to the rather limited expression of this mucin in the primitive embryoid body vascular system and early hematopoietic progenitor cells previously observed in wild-type ES cells." In spite of these caveats, analysis of erythroid and myeloid development in embryoid bodies transfected with both constructs showed that the deficiency observed in the 1-8D CD34-null mutant could be efficiently rescued by overexpression of CD34 with or without the cytoplasmic domain (Figs 4, 5) . In the case of myeloid development, the kinetics and extent of myeloid-positive embryoid bodies were reinstated in the transfected cells, whereas the doubly mutated ES cells carried under identical conditions for the same period of time showed no such recovery (Fig 5) . These data are consistent with a role for CD34 in the efficient induction of hematopoiesis in embryoid bodies and also suggest that the cytoplasmic domain appears to not be required for the hematopoietic function of CD34, at least in this in vitro system. Analysis of hematopoietic colony formation in CD34-null embryos. Although the embryoid body experiments suggested that there were hematopoietic defects in ES-derived progenitor cells lacking CD34, it was important to establish whether such defects could also be detected under more physiological conditions. Because the embryoid body system is thought to be representative of very early embryonic hematopoiesis,26 we first focussed on the progenitor activity in the yolk sac of CD34-mutant animals. Yolk sacs were dissected from individual embryos, and the equivalent numbers of unfractionated yolk sac cells were placed into methylcellulose cultures containing a variety of hematopoietic growth factors, whereas the embryos were used for DNA isolation and genotyping by the PCR. As can be seen from Fig 6, analysis of progenitor cells from the yolk sacs of CD34-null animals showed a significant decrease in total CFU (ie, erythroid, myeloid, and mixed colonies) progenitor cell number when compared with that for wild-type or heterozygous mutant animals. These data suggested, in agreement with the embryoid body analyses, that there were clear hematopoietic defects in embryonic yolk sac progenitor cells that lacked CD34. To examine whether such defects occurred later in embryonic development, similar types of experiments were performed using progenitors isolated from fetal liver. As Fig 6 shows, there was a similar significant decrease in erythroid and myeloid progenitors derived from the fetal livers of CD34-null animals as compared with that in wildtype or heterozygous-deficient animals. These data show that the hematopoietic defects observed in the CD34-null embryoid bodies are also observed in the yolk sac and fetal liver stages of embryonic hematopoiesis in animals lacking this mucin, which is consistent with an in vivo role for CD34 in embryonic hematopoiesis.
Hematopoiesis in adult animals lacking CD34. In spite of the significant decreases observed in the numbers of hematopoietic progenitor cells in embryos, normal Mendelian ratios of CD34-deficient animals were born after breeding CD34"+ heterozygous animals. In addition, differential analysis of the blood and BM of CD34-deficient animals did not show any significant differences in blood counts or cell types (data not shown). Finally, there were no obvious defects in the vascular development of these mutant animals (for example, see Fig 3) . Because considerably larger numbers of progenitors could be relatively easily obtained from hematopoietic sites of adult animals, more quantitative studies were performed using the BMs and spleens of CD34-deficient adult mice. As can be seen in Table 1 , analysis of the various progenitor types obtained from these hematopoietic sites showed a clear defect in the absolute numbers of these progenitor cells in CD34-deficient versus wild-type animals. Thus, whereas the total nucleated cellularity of the BM was not significantly different, the numbers of CFU-GM (myeloid), BFU-E (erythroid), and CFU-GEMM (mixed) colonies were decreased by as much as 73% in the mutant animals. Perhaps even more interestingly, the levels of high proliferative potential colony-forming cells (HF'P-CFCs), which represent a very early hematopoietic cell progenitor, were decreased by almost 70% in the mutant animals. In addition, whereas the total numbers of progenitors were somewhat less in the spleen as compared with that in the BM, similar decreases in precursor cell numbers were also observed in this hematopoietic compartment when compared between wild-type and CD34-deficient animals. Finally, whereas the numbers were too small to be significant for CFU-GM and BFU-E levels, the numbers of mixed colonies in the peripheral blood also appeared to be significantly decreased. Thus, these data were consistent with those obtained from the embryoid body and embryonic yolk sac and fetal liver studies and suggested that the loss of the CD34 antigen resulted in a considerable deficiency in the steady-state levels of hematopoietic cell progenitors of all types in adult hematopoietic sites.
Although the above data suggested that the loss of the CD34 glycoprotein resulted in hematopoietic defects, they did not address the mechanism by which these deficiencies use only.
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For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From became manifested. For example, these deficits may have been caused by decreased progenitor cell proliferation, survival, or retention in the BM. The last hypothesis would suggest an increased level of progenitor cells in the periphery, but measurements of progenitor cell activity in peripheral blood did not show a significant increase in this cell type in mutant animals ( Table 1) . To determine if the loss of this antigen had an effect on the ability of progenitor cells to be expanded, in vitro suspension culture studies were performed with unseparated whole BM from wild-type and CD34-null animals. Progenitor colony counts were performed at initial times and after 1 week of expansion in the presence of EPO, GM-CSF, steel factor, and flt3-ligand. As can be seen in Table 2 , whereas the BM from wild-type animals showed significant levels of progenitor expansion when cultured in the presence of a cocktail of growth factors, the BM isolated from CD34-deficient animals showed little or no expansion or, in some cases, a decrease in the number of progenitors produced. Thus, the outputs of progenitor cells in these experiments, starting with the same number of input nucleated cells (dividing output numbers of progenitors from wild-type by output numbers of progenitors from CD34-deficient mice), were 14.0X (CFU-GM), 8.8X (BFU-E), 22.7X (CFU-GEMM), and 5.3X (HPP-CFC) greater for wild-type as compared with that for CD34-null BM samples. These data are consistent with the supposition that the loss of CD34 results in profound defects in the ability of progenitor cells to expand in response to hematopoietic growth factors.
Hematopoietic recovery of CD34-null animals from sublethal irradiation. The above in vitro analyses were all consistent with the supposition that the loss of the CD34 antigen affected both the steady-state levels of embryonic and adult hematopoietic progenitors of all subclasses as well as the ability of progenitor cells to expand in vitro in response to growth factors. However, the survival of CD34-null animals, in addition to the apparent lack of effect on the levels of mature hematopoietic cells, suggested that these progenitor deficiencies may not have significant deleterious effects on the steady-state levels of mature blood cells. In addition, these experiments did not show any aspects of the ability of the BM of CD34-deficient animals to function under conditions of stress. Although the most stringent test of this functional aspect of BM is transplantation, because of the outbred nature of these animals, it was difficult to accomplish these experiments in the absence of several generations of inbreeding. Therefore, we decided to test the ability of the BMs of wild-type and CD34-deficient animals to regenerate normal levels of mature peripheral blood lineages in animals treated with sublethal doses of irradiation. As can be seen from Fig 7, sublethal doses of irradiation resulted in considerable decreases in the erythroid, myeloid, and platelet levels in both wild-type and CD34-deficient animals. Surprisingly, in spite of the fact that the CD34 animals show deficiencies in the steady-state levels of erythroid, myeloid, and mixed progenitor populations, they were, nevertheless, able to repopulate all three classes of peripheral blood cell types with kinetics that were similar to those observed in the wild-type population. Therefore, these data were consistent with the conclusion that the residual progenitor cell activity detected in the BM of CD34-deficient animals was adequate to allow for the rapid reconstitution of the irradiation-depleted peripheral blood cells.
DISCUSSION
The hematopoietic microenvironment is exquisitely controlled by a number of components including, for example, growth factors, cytokines, chemokines, and adhesion molecules. Many of the glycoproteins that are found to be expressed on early hematopoietic progenitor cells, such as the Colony-forming activity of yolk sac (A) and fetal liver (B) progenitor cells isolated from wild-type (+/+), CD34'" (+/-), and CD34"-(-/-) embryos. Yolk sacs or fetal livers were isolated from individual day-10.5 or day-l5 embryos, respectively, and the total CFUS per organ were determined in the presence of either EPO (BFU-E), GM-CSF (CFU-GM), and EPO + GM-CSF (total CFU-C) plus 11-1 and IL-3.
The remaining embryonic tissues were used for genotyping by the PCR. Colony counts were determined at day 14 without knowledge of the genotype. Each point in the graphs shows data obtained from a single embryo. At least three separate litters were analyzed, and all of the data were pooled in these graphs. P values, determined using a t w o tailed t-test, were as follows: (1) yolk sap total CFU: KO v HET, 1.001; KO v WT. c-kit, c-fms, and flk-2Mt3 tyrosine kinase receptors, bind to glycoprotein CD34, a heavily 0-glycosylated cell surface hematopoietic growth factors and, therefore, play relatively mucin, is one such protein. Unlike many of the other surface obvious roles in hematopoietic growth and differentiation.
glycoproteins found to be expressed on early progenitor However, there are a number of proteins on early hematopoicells, the predicted structure of the extracellular moiety of etic progenitors that have less recognizable functions. The this mucin, with both a highly 0-glycosylated N-terminal The results shown are the average of the assessment of five mice per group with each mouse studied individually; the cells from different mice were not pooled. Results are shown as mean f SD.
Abbreviation: ND, not done; KO, knockout.
* Not significant, P > .05.
t Significantly different from wild-type control, P < .0005.
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domain and a cysteine-rich region, does not give any conspicuous clues as to its possible function. Because this antigen is unambiguously expressed on hematopoietic progenitor cells that range from the earliest pluripotent stem cell to the more highly differentiated committed progenitors,6-* it has been previously hypothesized that this heavily glycosylated mucin must have a functional role in the physiology of these precursor cells. However, other than a limited number of in vitro studies using hematopoietic progenitor cell lines, very little data regarding the potential hematopoietic function of CD34 have been obtained. Here, we report that hematopoiesis is delayed in developing embryoid bodies deleted for the CD34 gene; that hematopoietic progenitors from the yolk sac, fetal liver, and adult BM and spleen are decreased in CD34-deficient animals; and that hematopoietic progenitor cells derived from BM of these mutant animals show a profound defect in their ability to expand ex vivo in response to various hematopoietic growth factors. Thus, the data reported here provide compelling evidence that CD34 is involved with the proliferation and/or maintenance of the hematopoietic progenitor cells in the embryo and adult.
Analysis of hematopoiesis in developing embryoid bodies lacking CD34 showed a significant lag in the kinetics of monocyte/macrophage and erythroid differentiation as well as a clear decrease in the absolute numbers of hematopoietically positive embryoid bodies. These results suggested that CD34 was required for the efficient production of hematopoietic progenitor cells in this in vitro developmental system. Because the analysis investigated the percentage of embryoid bodies that produced mature hematopoietic cells, and not the levels of hematopoiesis per embryoid body, the data were consistent with a role for CD34 in the initiation of the hematopoietic phenotype in these embryo-like structures. Alternatively, these results may also be interpreted to suggest that this glycoprotein was required for the efficient conversion of preexisting pluripotential cells to more committed progenitor cells and eventually to differentiated myeloid and erythroid cells. In light of the experiments described here that showed that there are defects in the in vitro expansion of CD34-negative adult BM progenitors in response to growth factors, it is likely that the second interpretation is the correct one. These data were also interesting in light of previous work that showed an upregulation of CD34 expression, as detected by the PCR, as embryoid bodies developed a hematopoietic phenotype, a result that correlates with a requirement for CD34 during embryoid body hematopoiesis. In addition, other analyses have shown that CD34 is clearly expressed on developing vessels and hematopoietic progenitor cells in embryoid bodies.".l2 Therefore, these data together are consistent with the hypothesis that CD34 is involved with some aspect of hematopoietic development in this differentiating system.
In agreement with the importance of CD34 to hematopoietic development during embryoid body formation were data that showed that ectopic expression of CD34 in the CD34-null embryoid bodies resulted in a reversal of this hematopoietic defect. This result was obtained despite the fact that, because of the use of a strong CMV promoter, normal CD34 regulation was lost in these transfected cells, with the result that higher levels of CD34 were observed as well as a loss of tissue-specific expression. In addition, the fact that a mutated form of CD34, which lacked the majority of the cytoplasmic domain, was able to mediate a similar degree of hematopoietic rescue suggested that the important functional region of the mucin was restricted to the extracellular domain. Thus, it might be conjectured that previous studies that showed serine phosphorylation of the cytoplasmic domain of this mucin in response to protein kinase C activation may have been showing a functional aspect of this glycoprotein that is not necessary for its hematopoietic capacity? Alternatively, the high degree of expression of the mucin in our transfection system may have overcome any need for signals transmitted through this phosphorylation event or other intracellular signaling phenomena. Interestingly, an alternatively spliced form of CD34 that lacks a portion of the cytoplasmic domain containing phosphorylation sites has been described, although the functional significance of this modification is unknown.*' Suffice it to say that the embryoid body transfection data provide clear evidence consistent with the importance of CD34 in embryoid body hematopoiesis as well as support the hypothesis that the extracellular domain of CD34 use only. is sufficient to mediate the rescue of CD34-null embryoid bodies deficient in erythroid and monocyte/macrophage differentiation.
The effects of CD34 loss on embryoid body hematopoiesis and the decrease in progenitor numbers observed in both embryonic and adult hematopoietic sites may be explained by effects on proliferation, survival, or retention of progeniof CD34-deficient animals, and, in the case of mixed progenitors, there was an actual decrease in the peripheral compartment. Although it is difficult to differentiate the influences of cell survival versus proliferation on steady-state levels of progenitors, the decreased kinetics of hematopoiesis in the embryoid body experiments, together with the profound loss of proliferation of progenitor cells in in vitro expansion studies, argues strongly for a role for CD34 in the proliferation of hematopoietic cell progenitors. Thus, it seems likely that this mucin-like molecule affects the hematopoietic microenvironment, the progenitor cells, or both to allow for efficient expansion of these precursor cells in vivo.
How might CD34 operate in this context? Three possible functions of this mucin might involve adhesion, signaling, or growth-factor presentation. For example, CD34 has been previously hypothesized to be involved with cell adhesion, and there are currently data that show that an appropriately glycosylated form of this mucin is involved with the adherence of lymphocytes to high-walled endothelial cells of the lymph node. This adherence is mediated by the interaction of the lectin domain of the adhesion molecule L-selectin with highly modified 0-linked carbohydrates presented by CD34." A similar adhesive mechanism might be proposed for hematopoietic cell CD34,2* in which binding interactions between carbohydrates presented by the mucin and a lectinlike counter-receptor on the hematopoietic stroma might be required for appropriate maturation of the progenitor cells. Of course, because CD34 is often expressed on both the progenitor cells as well as on the stromal cell^,".^' it is possible that such adhesive interactions might work in a cooperative manner. Interestingly, confocal microscopy studies of the yolk sac blood islands,"," visualization of blood island hematopoietic cell-stromal cultures,13 as well as electron microscopic analyses of intra-embryonic hematopoiesis (F. Dieterlein-Lievre, I. Godin, and L. Lasky, unpublished observations) have all shown obvious and, in some cases, high-avidity adhesion between the CD34 progenitor cells and the endothelium of hematopoietic organs. If CD34 is involved with these binding events, then the loss of such adhesive interactions in CD34-null animals might result in decreased progenitor cell proliferation and diminished steady-state levels of these cells in hematopoietic regions. Indeed, previous studies have highlighted the importance of other adhesion molecules to the expansion of progenitor cells in v i t r~.~' -~~ By analogy with previous studies, the finding that the extracellular domain appears critical for hematopoiesis in embryoid bodies supports the possibility that this site might present 0-linked carbohydrates to a lectin-like molecule on an opposing cell. However, the rescue of hematopoiesis by the cytoplasmic domain deletion mutant does not use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From support a role for CD34 in cellular signaling, at least via the small intracellular domain of this mucin. It is possible that CD34 binding to a signaling molecule on an opposing cell, either via a protein-carbohydrate or protein-protein interaction, might mediate a signal that is critical for hematopoietic progenitor cell proliferation, although there is little precedent for this type of interaction. Finally, by analogy with observations of growth factor or transforming growth factor$ activation events, it is also feasible that CD34 acts to efficiently present a soluble factor(s) to a receptor(s) on hematopoietic or stromal cell lines to enable efficient progenitor cell prolife r a t i~n .~~
In this hypothesis, a growth or differentiation factor might bind to carbohydrates in the mucin-like region of CD34, with the result that the factors might be more highly concentrated on the cell surface. This last conjecture would suggest that deletion of the mucin-like domain would result in a form of CD34 that was incapable of rescuing embryoid body hematopoiesis. However, it should be noted that removal of an undetermined fraction of the mucin-like region of CD34 by the 0-sialoglycoprotease does not appear to significantly inhibit progenitor cell growth in One possibly counterintuitive result obtained here is that CD34-deficient animals appear to repopulate peripheral blood lineages after sublethal irradiation with kinetics that are very similar to those observed for wild-type animals, in spite of the fact that BM and spleen progenitors under steadystate conditions are decreased by as much as 70% to 80%. The most likely explanation for this result is that the BM and spleen compartments have excess capacity for repopulating the periphery. Thus, if only a minor fraction of the available progenitor cells are recruited when peripheral cell levels decrease below a critical point, then the kinetics of repopulation would not be significantly different in the CD34-null animals. In support of this hypothesis, only a small fraction of BM stem cells appears to be required for complete hematopoietic reconstitution of lethaly irradiated recipient^.^^ An alternative hypothesis is that the available progenitor cells in the BM of the mutant animals are recruited at a relatively higher rate to the periphery, either by an increased migration from the BM or spleen or by an increased proliferative response of the residual precursor cells. Finally, it is possible that unidentified compensatory mechanisms are operative in the hematopoietic compartments of CD34-deficient animals. These possibilities are testable by a number of means including repeated depletion of the BM with 5-A uorouridine as well as transplantation of animals with CD34-deficient BM cells.
In summary, the data reported in this report suggest that CD34 is an important component of the hematopoietic systems of embryos and adults. The relative contributions of CD34 on the endothelial and hematopoietic progenitor sides of these interactions can now be analyzed. In addition, the important functional domain(s) responsible for CD34 activity can now also be examined in one or more of the systems described here. Finally, the mechanism by which CD34 mediates the hematopoietic effects observed here may eventudly illuminate potentially new mechanisms of inductive differentiation.
